Floatz logo

Romidepsin

T Lymphoblastic Leukemia/Lymphoma

Ohio State University Comprehensive Cancer CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

49 Active assets in the T Lymphoblastic Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Children's Oncology Group
Phase 3BB
PREDNISONE TABLETS
Children's Oncology Group
Phase 3BB
Cytosin-Arabinosid
Princess Maxima Center for Pediatric Oncology
Phase 3BB
ETOPOSIDE
Children's Cancer Group, China
Phase 3BB
Daunorubicin
Children's Oncology Group
Phase 3B

View all 50 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →